Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Knighty Tin who wrote (30551)	8/5/1998 6:12:00 PM
From: Knighty Tin	Respond to of 132070

To All, I am recommending a, "Yikes, get a rope, stone the bastard" biotech stock. SangStat (SANG) is an old favorite of mine and the recent drop in price has put it back on my list. The company has a generic version of cyclosporine awaiting FDA approval, which I expect by Halloween. That is a $1.3 billion market currently owned by Novartis. Sang Stat can easily cut Novartis's high prices and still make tons of money. Yes, there is likely to be lawsuits, but this is one that will have big revenues next year, IMHO. The stock was over $30 recently (I sold my lat third at $29 several months ago), so I consider $21 a bargain. Can it go lower? Is it a biotech stock? The answer to both questions is yes, but I think that once the moolah starts rolling in, this is a mid-40s stock. Good luck, MB